Myelodysplastic Syndromes

Major Study Finds Persistent Underuse and Disparities in Guideline-Recommended MDS Therapy

Medicare claims analysis shows stark gender, racial treatment gaps and widespread early discontinuation that undermine survival gains from hypomethylating agents.